TABLE 2.

Cost-effectiveness analysis and incremental cost-effectiveness ratios with regard to lowering blood pressure

	C (US$)	E		C/E		ΔC/ΔE
		SBP	DBP	SBP	DBP	SBP	DBP
Women (n = 380)
NH	47.2	33.8 ± 14.9	16.3 ± 8.9	1.4	2.9	ND	ND
NM	62.5	34.1 ± 14.7	16.8 ± 8.8	1.8	3.7	51.0	30.6
Men (n = 243)
NH	49.5	35.1 ± 17.5	17.9 ± 10.3	1.4	2.8	ND	ND
NM	62.2	30.6 ± 16.9	16.0 ± 10.0	2.0	3.9	−2.8	−6.7
≤65 years (n = 530)
NH	47.1	34.1 ± 16.0	16.9 ± 9.5	1.4	2.8	ND	ND
NM	61.7	33.1 ± 15.9	16.7 ± 9.2	1.9	3.7	−14.6	−73
>65 years (n = 93)
NH	53.9	35.7 ± 15.1	17.0 ± 9.1	1.5	3.2	ND	ND
NM	66.1	30.2 ± 15.2	15.2 ± 10.0	2.2	4.3	−2.2	−6.7
Total (n = 623)
NH	48.0	34.3 ± 15.9	16.9 ± 9.6	1.4	2.8	Null	Null
NM	63.4	32.6 ± 15.8	16.4 ± 9.4	1.9	3.8	−8.5	−28.8

C, average cost per patient; E, effectiveness; ND, no data; NH, nitrendipine+hydrochlorothiazide; NM, nitrendipine+metoprolol.